BYSI BeyondSpring, Inc.
$0.47▲ +1.87%
Healthcare
Other
Volume 402
Avg Volume (10D) 41.7K
Key Metrics & Fundamentals
Market Cap
$19.27M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.42 - 2.44
% vs 50 MA
-31.71%
% vs 200 MA
-64.48%
RSI-14
33.6
MACD Histogram
-0.0200
Beta (1Y vs SPY)
0.87
Free Cash Flow
-$3.77M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.77M
COGS
–
Operating Exp
$1.73M
Operating Income
-$1.73M
EBIT
-$1.73M
Pretax Income
-$1.65M
Net Income
-$849,000
EPS (Diluted)
-0.02
Price & Volume History
Loading chart…
Recent News
BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances
InvestorsHub · Sep 29, 2026 10:43 AM ET
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
GlobeNewswire · Sep 29, 2026 7:01 AM ET
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Aug 14, 2026 5:15 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See BYSI's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.